DE602005021970D1 - Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen - Google Patents

Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen

Info

Publication number
DE602005021970D1
DE602005021970D1 DE602005021970T DE602005021970T DE602005021970D1 DE 602005021970 D1 DE602005021970 D1 DE 602005021970D1 DE 602005021970 T DE602005021970 T DE 602005021970T DE 602005021970 T DE602005021970 T DE 602005021970T DE 602005021970 D1 DE602005021970 D1 DE 602005021970D1
Authority
DE
Germany
Prior art keywords
pain
nucleoside
chemotherapy
treatment
bone cancer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602005021970T
Other languages
English (en)
Inventor
Bettina Beyreuther
Thomas Stoehr
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
UCB Pharma GmbH
Original Assignee
UCB Pharma GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04020402A external-priority patent/EP1629839A1/de
Application filed by UCB Pharma GmbH filed Critical UCB Pharma GmbH
Publication of DE602005021970D1 publication Critical patent/DE602005021970D1/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
DE602005021970T 2004-08-27 2005-08-22 Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen Active DE602005021970D1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US60481004P 2004-08-27 2004-08-27
EP04020402A EP1629839A1 (de) 2004-08-27 2004-08-27 Verwendung von Peptidverbindungen zur Behandlung von Knochenkrebsschmerz sowie von Chemotherapie- oder Nukleosid-induziertem Schmerz
PCT/EP2005/009067 WO2006021412A2 (en) 2004-08-27 2005-08-22 Use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain

Publications (1)

Publication Number Publication Date
DE602005021970D1 true DE602005021970D1 (de) 2010-08-05

Family

ID=35456911

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602005021970T Active DE602005021970D1 (de) 2004-08-27 2005-08-22 Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen

Country Status (17)

Country Link
US (2) US7687553B2 (de)
EP (1) EP1781276B1 (de)
JP (1) JP2008510758A (de)
KR (1) KR20070045271A (de)
AR (1) AR050612A1 (de)
AT (1) ATE471717T1 (de)
AU (1) AU2005276634B2 (de)
BR (1) BRPI0514721A (de)
CA (1) CA2573125A1 (de)
DE (1) DE602005021970D1 (de)
EA (1) EA014055B1 (de)
IL (1) IL181383A0 (de)
MX (1) MX2007002269A (de)
NO (1) NO20071585L (de)
NZ (1) NZ552651A (de)
PL (1) PL1781276T3 (de)
WO (1) WO2006021412A2 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19633169A1 (de) 1996-08-17 1998-02-19 Teves Gmbh Alfred Elektromotor-/Pumpenaggregat
EP1243262B1 (de) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
ES2325995T3 (es) * 2003-12-02 2009-09-28 Schwarz Pharma Ag Nueva utilizacion de compuestos peptidicos para tratamiento del dolor neuropatico central.
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
KR20070007931A (ko) 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
KR20070045271A (ko) 2004-08-27 2007-05-02 쉬바르츠파르마에이지 골암 통증, 화학요법- 및 뉴클레오시드- 유도 통증의치료를 위한 펩티드 화합물의 용도
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2509939A4 (de) * 2009-09-23 2013-09-18 Univ North Carolina Neuartige n-benzylamid-substituierte derivate aus 2-(acylamid-)essigsäure und 2-(acylamid-)propionsäuren: starke neurologische wirkstoffe
EP2468261A1 (de) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulierung von Lacosamid
WO2012084126A2 (en) 2010-12-02 2012-06-28 Ucb Pharma Gmbh Formulation of lacosamide
US9134395B2 (en) 2012-03-07 2015-09-15 Freescale Semiconductor, Inc. Method for testing comparator and device therefor
CN108292823A (zh) * 2016-01-07 2018-07-17 松下知识产权经营株式会社 发光装置

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2937698A1 (de) * 1979-09-18 1981-04-02 A. Nattermann & Cie GmbH, 5000 Köln N-propionylsarcosinanilide, deren herstellungsverfahren und arzneimittel auf deren basis
FR2480747A1 (fr) * 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
US4533657A (en) * 1981-07-24 1985-08-06 Sterling Drug Inc. Analgesic dipeptide amides and method of use and composition thereof
FR2518088B1 (fr) * 1981-12-16 1987-11-27 Roques Bernard Nouveaux derives d'aminoacides, et leur application therapeutique
US4510082A (en) * 1983-03-07 1985-04-09 Eli Lilly And Company Pharmacologically active peptides
JPH0680079B2 (ja) * 1984-11-09 1994-10-12 エーザイ株式会社 ポリペプチド
US5378729A (en) * 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
GB9103454D0 (en) 1991-02-19 1991-04-03 Pfizer Ltd Therapeutic agents
US5656267A (en) * 1991-08-22 1997-08-12 Sagen; Jacqueline Implantable cells that alleviate chronic pain in humans
TW217417B (de) 1991-12-04 1993-12-11 Manyu Seiyaku Kk
US5585358A (en) * 1993-07-06 1996-12-17 Yissum Research Development Corporation Of The Hebrew University Of Jerusalem Derivatives of valproic acid amides and 2-valproenoic acid amides, method of making and use thereof as anticonvulsant agents
GB9504854D0 (en) * 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
US5536853A (en) * 1994-04-11 1996-07-16 Chiron Corporation Opiate receptor ligands
MY113062A (en) 1994-05-10 2001-11-30 The Wellcome Foundation Ltd Amide derivatives and their therapeutic use
US5508266A (en) * 1994-06-22 1996-04-16 Ciba-Geigy Corporation Gem-disubstituted amino acid derivatives
PL183510B1 (pl) 1994-10-05 2002-06-28 Darwin Discovery Ltd Związki peptydowe oraz środek farmaceutyczny
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US5780589A (en) * 1994-11-30 1998-07-14 The United States Of America As Represented By The Department Of Health And Human Services Ultraselective opioidmimetic peptides and pharmacological and therapeutic uses thereof
US5760038A (en) * 1995-02-06 1998-06-02 Bristol-Myers Squibb Company Substituted biphenyl sulfonamide endothelin antagonists
US5849737A (en) * 1995-04-14 1998-12-15 The Regents Of The University Of California Compositions and methods for treating pain
WO1997003677A1 (en) * 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
US6114390A (en) * 1995-11-30 2000-09-05 Karl Thomae Gmbh Amino acid derivatives, pharmaceutical compositions containing these compounds and processes for preparing them
US6037324A (en) * 1996-01-04 2000-03-14 Leukosite, Inc. Inhibitors of MAdCAM-1-mediated interactions and methods of use therefor
GB9601724D0 (en) * 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614542A1 (de) * 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
US5773455A (en) * 1996-06-28 1998-06-30 Biomeasure, Incorporated Inhibitors of prenyl transferases
US6277825B1 (en) * 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
JP3693258B2 (ja) * 1996-07-24 2005-09-07 ワーナー―ランバート・コンパニー イソブチルｇａｂａまたはその誘導体を含有する鎮静剤
US6589994B1 (en) 1996-08-30 2003-07-08 Nps Pharmaceuticals, Inc. Treating a variety of pathological conditions, including spasticity and convulsions, by effecting a modulation of CNS activity with isovaleramide, isovaleric acid, or a related compound
US6126939A (en) * 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US5866585A (en) * 1997-05-22 1999-02-02 Synchroneuron, Llc Methods of treating tardive dyskinesia using NMDA receptor antagonists
DE69833858T2 (de) 1997-07-08 2007-02-22 Ono Pharmaceutical Co. Ltd. Aminosäurederivate
US6737408B1 (en) * 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
AU7696098A (en) 1997-08-11 1999-03-01 Algos Pharmaceutical Corporation Substance p inhibitors in combination with nmda-blockers for treating pain
DE19743143A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
ID24278A (id) 1997-10-31 2000-07-13 Basf Ag Turunan-turunan asam karboksilat baru dengan rantai sisi amida, pembuatan dan penggunaannya sebagai reseptor antagonis endotelin
US6028102A (en) * 1998-02-24 2000-02-22 Yissum Research Development Company Of The Hebrew University Of Jerusalem Anticonvulsant drugs and pharmaceutical compositions thereof
US6596719B1 (en) 1999-09-03 2003-07-22 Actelio Pharmaceuticals Ltd. 6 alkoxy-4-pyrimidinyl bis-sulfonamides
SE0001373D0 (sv) 2000-04-13 2000-04-13 Karolinska Innovations Ab NPY Y1 receptor agonists and antagonists
IL154470A0 (en) 2000-08-17 2003-09-17 Teva Pharma Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
PT1365787E (pt) * 2000-08-25 2007-06-29 Res Corp Technologies Inc Utilização de anticonvulsivantes de aminoácidos para tratamento da dor.
US7112612B2 (en) 2000-11-21 2006-09-26 Ucb S.A. N-alkylated GABA compounds, processes for their preparation and their use as medicaments
EP1243262B1 (de) * 2001-03-20 2006-05-31 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen bei der Behandlung von nicht-neuropathischem Entzündungsschmerz
ES2185606T3 (es) * 2001-03-21 2003-05-01 Sanol Arznei Schwarz Gmbh Nuevo uso de una clase de compuestos peptidicos para tratamiento de la alodinia u otros tipos diferentes de dolor cronico o fantasma.
JP2004529132A (ja) 2001-03-27 2004-09-24 アクテリオン　ファマシューティカルズ　リミテッド １，２，３，４−テトラヒドロイソキノリン誘導体
BR0209199A (pt) 2001-04-26 2006-02-07 Bristol Myers Squibb Co Controle de campactabilidade através de cristalização
ITMI20011308A1 (it) 2001-06-21 2002-12-21 Nicox Sa Farmaci per il dolore cronico
AU2003243180A1 (en) * 2002-05-17 2003-12-12 Xenoport, Inc. Amino acid conjugates providing for sustained systemic concentrations of gaba analogues
EP1546134B1 (de) 2002-08-05 2007-05-02 Eli Lilly And Company Piperazinsubstituierte arylbenzodiazepine
PL376993A1 (pl) 2002-11-11 2006-01-23 Bayer Healthcare Ag Pochodne fenylo- lub heteroarylo-aminoalkanów jako antagoniści receptora IP
AU2003283160A1 (en) 2002-11-18 2004-06-15 Bradley J. Steeves Shrew paralytic peptide for use in neuromuscular therapy
US7687080B2 (en) * 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
BR0317392A (pt) 2002-12-19 2005-12-20 Pharmacia Corp Formulação não-higroscópica incluindo uma droga higroscópica
JP2006515327A (ja) 2003-01-30 2006-05-25 ダイノジェン ファーマシューティカルズ， インコーポレイテッド ナトリウムチャネル調節因子を用いた下部尿路障害を処置するための方法
AU2004207009A1 (en) 2003-01-30 2004-08-12 Dynogen Pharmaceuticals, Inc. Use of sodium channel modulators for treating gastrointestinal tract disorders
US20040265375A1 (en) 2003-04-16 2004-12-30 Platteeuw Johannes J. Orally disintegrating tablets
US20040266743A1 (en) 2003-05-09 2004-12-30 Pharmacia Corporation Combination of an aldosterone receptor antagonist and a renin inhibitor
US7320675B2 (en) * 2003-08-21 2008-01-22 Cardiac Pacemakers, Inc. Method and apparatus for modulating cellular metabolism during post-ischemia or heart failure
EP1537862A1 (de) 2003-12-02 2005-06-08 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von zentralen neuropathische-Schmerzen
ES2325995T3 (es) * 2003-12-02 2009-09-28 Schwarz Pharma Ag Nueva utilizacion de compuestos peptidicos para tratamiento del dolor neuropatico central.
EP1541138A1 (de) 2003-12-05 2005-06-15 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Status Epilepticus und ähnlicher Zustände
US20060009384A1 (en) * 2003-12-05 2006-01-12 David Rudd Novel use of peptide compounds for treating status epilepticus or related conditions
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
EP1579858A1 (de) 2004-03-26 2005-09-28 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von diabetishen Neuropathie
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
KR20070007931A (ko) * 2004-04-16 2007-01-16 쉬바르츠파르마에이지 만성 두통의 예방 및 치료를 위한 펩티드 화합물의 용도
EP1604654A1 (de) * 2004-05-18 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Dyskynesien
EP1604656A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von amyotropher Lateralsklerose (ALS)
EP1604655A1 (de) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Neue Verwendung von Peptidverbindungen zur Behandlung von Trigeminusneuralgie
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
KR20070045271A (ko) 2004-08-27 2007-05-02 쉬바르츠파르마에이지 골암 통증, 화학요법- 및 뉴클레오시드- 유도 통증의치료를 위한 펩티드 화합물의 용도
EP1642889A1 (de) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Verbessertes Syntheseschema für Lacosamid
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
EP1688137A1 (de) 2005-01-28 2006-08-09 Schwarz Pharma Ag SPM 927 zur Co-Therapie der Schizophrenie
EP1754476A1 (de) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamid (SPM 927) zur Behandlung von Myalgien, z.B. Fibromyalgie
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
EA027836B1 (ru) * 2006-06-15 2017-09-29 ЮСиБи ФАРМА ГМБХ Фармацевтическая комбинация для профилактики, облегчения и/или лечения приступов эпилепсии и ее применение
EP1873527A1 (de) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Verfahren zur Identifizierung von CRMP-Modulatoren
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP2214657A1 (de) * 2007-10-23 2010-08-11 UCB Pharma GmbH Verbindungen zur behandlung von demyelisationserkrankungen

Also Published As

Publication number Publication date
BRPI0514721A (pt) 2008-06-24
NO20071585L (no) 2007-04-30
AU2005276634A1 (en) 2006-03-02
EP1781276B1 (de) 2010-06-23
NZ552651A (en) 2010-07-30
KR20070045271A (ko) 2007-05-02
WO2006021412A3 (en) 2006-04-27
US20060046957A1 (en) 2006-03-02
EA014055B1 (ru) 2010-08-30
MX2007002269A (es) 2007-06-15
IL181383A0 (en) 2008-03-20
US8536137B2 (en) 2013-09-17
WO2006021412A2 (en) 2006-03-02
US20100029543A1 (en) 2010-02-04
JP2008510758A (ja) 2008-04-10
PL1781276T3 (pl) 2010-11-30
AU2005276634B2 (en) 2011-03-24
CA2573125A1 (en) 2006-03-02
ATE471717T1 (de) 2010-07-15
EA200700493A1 (ru) 2007-08-31
US7687553B2 (en) 2010-03-30
EP1781276A2 (de) 2007-05-09
AR050612A1 (es) 2006-11-08

Similar Documents

Publication Publication Date Title
DE602005021970D1 (de) Verwendung von peptidverbindungen zur behandlung von schmerzen durch knochenkrebs, chemotherapie- und nucleosid-bedingten schmerzen
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602005007717D1 (de) Imidazolverbindungen zur behandlung von neurodegenerativen erkrankungen
ATE395871T1 (de) Marknagel zur behandlung von proximalen oberschenkelknochenbrüchen
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE527241T1 (de) Pyridiazinonderivate zur behandlung von tumoren
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE515261T1 (de) Zusammensetzungen zur behandlung von diabetes
ATE453653T1 (de) Platinkomplexe zur behandlung von tumoren
DE60313021D1 (de) 4-tetrazolyl-4-phenylpiperidindervate zur schmerzbehandlung
DE602006009899D1 (de) Verwendung von oxycodon zur behandlung von viszeralem schmerz
DE502006007982D1 (de) Neue arzneimittelkombinationen zur behandlung von atemwegserkrankungen
ATE443704T1 (de) Pyridopyrimidinone zur behandlung von krebserkrankungen
DE602006017367D1 (de) Amino-oxo-indolyliden-verbindungen zur verwendung in der behandlung von juckender kopfhaut
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
DE602004022153D1 (de) Verbindungen zur behandlung von obesitas
DE602005013650D1 (de) Proteinhydrolysat zur behandlung von müdigkeit
DE602004022035D1 (de) Verwendung von pthalide derivativen zur behandlung
DE602004019576D1 (de) Zur behandlung von schmerzen geeignete piperazine
DE602006013009D1 (de) Pharmazeutische zusammensetzung von mahanin zur behandlung von prostatakrebs
DE602005013287D1 (de) Zusammensetzung zur behandlung von leder
ATE482707T1 (de) 1-ä2h-1-benzopyran-2-on-8-ylü- piperazin- derivate zur behandlung von schmerzen
DE602005019770D1 (de) Medizinische zusammensetzung zur behandlung von krebs oder diabetes